California State Teachers Retirement System Has $4.14 Billion Stock Position in Boston Scientific Corporation $BSX

California State Teachers Retirement System grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 4,113.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 96,909,037 shares of the medical equipment provider’s stock after purchasing an additional 94,609,083 shares during the period. California State Teachers Retirement System owned approximately 0.07% of Boston Scientific worth $4,136,078,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BSX. Kelleher Financial Advisors bought a new stake in shares of Boston Scientific in the second quarter worth $25,000. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at about $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.1%

Shares of NYSE:BSX opened at $45.04 on Thursday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $108.07. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business’s 50-day moving average is $47.08 and its 200-day moving average is $54.97. The company has a market capitalization of $65.27 billion, a price-to-earnings ratio of 18.23, a P/E/G ratio of 1.04 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported progress in its RESPI clinical study, which is evaluating wearable technology for breathing monitoring. The update supports the company’s longer-term innovation pipeline, although it is not expected to materially affect near-term revenue. Boston Scientific’s RESPI Study Signals Progress in Wearable Breathing Monitoring
• Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target from $60 to $56. The revised target still implies substantial upside from recent trading levels, indicating the analyst views the cyberattack disruption as manageable over time. BTIG Research price-target update
• Neutral Sentiment: Recent commentary is examining whether investors should buy or sell BSX puts, reflecting elevated uncertainty and volatility following the earnings warning rather than a new fundamental development. BSX Stock: Is It Time To Buy Or Sell Puts?
• Negative Sentiment: Boston Scientific said it is unlikely to meet its 2026 net-sales growth and EPS guidance. The cyberattack disrupted manufacturing and order shipments worldwide and is expected to materially affect both third-quarter and full-year results, driving the recent decline in shares. Boston Scientific says cyberattack likely to hurt 2026 sales and profit
• Negative Sentiment: Analysts also cited pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses. While product launches and cost savings may support recovery by 2028, the combination of weaker near-term demand and cybersecurity-related disruption increases execution risk. Boston Scientific’s 2026 Growth Outlook Weakens

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. Leerink Partners set a $60.00 price objective on Boston Scientific in a research report on Thursday, July 30th. Mizuho reduced their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. BTIG Research decreased their target price on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a research report on Wednesday. Raymond James Financial restated an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $71.46.

Insider Transactions at Boston Scientific

In related news, Director David Habiger acquired 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.